Clinical trial
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients…
NCT00409578 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00409578 |
|---|---|
| Title | Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome |
| Official title | A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multinational Clinical Trial to Evaluate the Efficacy of Aliskiren and Valsartan Versus Placebo in Lowering Levels on NT-proBNP in Stabilized Patients Post Acute Coronary Syndromes |
| Lead sponsor | Novartis, Industry |
| Collaborators | The TIMI Study Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Post Acute Coronary Syndrome, Myocardial Ischemia |
| Intervention type | Drug |
| Interventions | Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg |
| Enrollment | 1,101 |
| Start date | Feb 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Dec 11, 2006 |
| Last update posted | Apr 19, 2011 |
| Countries | Belgium, Canada, Czechia, Germany, Hungary, Netherlands, Poland, Russia, Spain, Sweden, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: